Literature DB >> 23500283

Outcomes associated with microalbuminuria: effect modification by chronic kidney disease.

Csaba P Kovesdy1, Evan H Lott, Jun Ling Lu, Sandra M Malakauskas, Jennie Z Ma, Miklos Z Molnar, Kamyar Kalantar-Zadeh.   

Abstract

OBJECTIVES: This study sought to compare the association of microalbuminuria with outcomes in patients with different comorbidities.
BACKGROUND: The risk of adverse outcomes associated with lower levels proteinuria has been found to be linearly decreasing with even low-normal levels of microalbuminuria. It is unclear whether comorbid conditions change these associations.
METHODS: We examined the association of urine microalbumin-creatinine ratio (UACR) with mortality and the slopes of estimated glomerular filtration rate (eGFR) in a nationally representative cohort of 298,875 U.S. veterans. Associations of UACR with all-cause mortality overall and in subgroups of patients with and without diabetes mellitus, hypertension, cardiovascular disease, congestive heart failure, and advanced chronic kidney disease (CKD) were examined in Cox models, and with the slopes of eGFR in linear and logistic regression models.
RESULTS: Very low levels of UACR were linearly associated with decreased mortality and less progression of CKD overall: adjusted mortality hazard ratio and estimated glomerular filtration rate slope (95% confidence interval [CI]) associated with UACR ≥200 μg/mg, compared to <5 μg/mg were 1.53 (95% CI: 1.38 to 1.69, p < 0.001) and -1.59 (95% CI: -1.83 to -1.35, p < 0.001). Similar linearity was present in all examined subgroups, except in patients with CKD in whom a U-shaped association was present and in whom a UACR of 10 to 19 was associated with the best outcomes.
CONCLUSIONS: The association of UACR with mortality and with progressive CKD is modified in patients with CKD, who experience higher mortality and worse progression of CKD with the lowest levels of UACR. Proteinuria-lowering interventions in patients with advanced CKD should be implemented cautiously, considering the potential for adverse outcomes.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23500283      PMCID: PMC3625505          DOI: 10.1016/j.jacc.2012.11.071

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

Review 2.  Renal dysfunction complicating the treatment of hypertension.

Authors:  Biff F Palmer
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

3.  Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.

Authors:  Hans L Hillege; Vaclav Fidler; Gilles F H Diercks; Wiek H van Gilst; Dick de Zeeuw; Dirk J van Veldhuisen; Rijk O B Gans; Wilbert M T Janssen; Diederick E Grobbee; Paul E de Jong
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

4.  Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron.

Authors:  J C Pelayo; J Y Westcott
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

Review 6.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

7.  Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study.

Authors:  Matthew F Yuyun; Kay-Tee Khaw; Robert Luben; Ailsa Welch; Sheila Bingham; Nicholas E Day; Nicholas J Wareham
Journal:  Int J Epidemiol       Date:  2004-02       Impact factor: 7.196

8.  Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes.

Authors:  Klaus Klausen; Knut Borch-Johnsen; Bo Feldt-Rasmussen; Gorm Jensen; Peter Clausen; Henrik Scharling; Merete Appleyard; Jan Skov Jensen
Journal:  Circulation       Date:  2004-06-21       Impact factor: 29.690

9.  Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway.

Authors:  Solfrid Romundstad; Jostein Holmen; Kurt Kvenild; Hans Hallan; Hanne Ellekjaer
Journal:  Am J Kidney Dis       Date:  2003-09       Impact factor: 8.860

10.  Renal histopathology in hypertensive diabetic patients.

Authors:  G Ditscherlein
Journal:  Hypertension       Date:  1985 Nov-Dec       Impact factor: 10.190

View more
  25 in total

1.  Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study.

Authors:  Csaba P Kovesdy; Anthony J Bleyer; Miklos Z Molnar; Jennie Z Ma; John J Sim; William C Cushman; L Darryl Quarles; Kamyar Kalantar-Zadeh
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

2.  Age and Outcomes Associated with BP in Patients with Incident CKD.

Authors:  Csaba P Kovesdy; Ahmed Alrifai; Elvira O Gosmanova; Jun Ling Lu; Robert B Canada; Barry M Wall; Adriana M Hung; Miklos Z Molnar; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-21       Impact factor: 8.237

3.  Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans.

Authors:  Miklos Z Molnar; Istvan Mucsi; Marta Novak; Zoltan Szabo; Amado X Freire; Kim M Huch; Onyebuchi A Arah; Jennie Z Ma; Jun L Lu; John J Sim; Elani Streja; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Thorax       Date:  2015-06-02       Impact factor: 9.139

4.  Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans.

Authors:  Elvira O Gosmanova; Jun L Lu; Elani Streja; William C Cushman; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Hypertension       Date:  2014-08-04       Impact factor: 10.190

5.  Pain and Kidney Function Decline and Mortality: A Cohort Study of US Veterans.

Authors:  Vanessa Ravel; Seyed-Foad Ahmadi; Elani Streja; Jonathan A Sosnov; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Joline L T Chen
Journal:  Am J Kidney Dis       Date:  2016-04-20       Impact factor: 8.860

6.  Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans.

Authors:  Elvira O Gosmanova; Miklos Z Molnar; Ahmed Alrifai; Jun L Lu; Elani Streja; William C Cushman; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Am J Nephrol       Date:  2015-09-24       Impact factor: 3.754

7.  Association of incident restless legs syndrome with outcomes in a large cohort of US veterans.

Authors:  Miklos Z Molnar; Jun L Lu; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  J Sleep Res       Date:  2016-02       Impact factor: 3.981

Review 8.  The next generation of therapeutics for chronic kidney disease.

Authors:  Matthew D Breyer; Katalin Susztak
Journal:  Nat Rev Drug Discov       Date:  2016-05-27       Impact factor: 84.694

9.  Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.

Authors:  Miklos Z Molnar; Hazem M Alhourani; Barry M Wall; Jun L Lu; Elani Streja; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

10.  Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease.

Authors:  Csaba P Kovesdy; Jun L Lu; Miklos Z Molnar; Jennie Z Ma; Robert B Canada; Elani Streja; Kamyar Kalantar-Zadeh; Anthony J Bleyer
Journal:  JAMA Intern Med       Date:  2014-09       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.